{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:24:09Z","timestamp":1792686249507,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current guidelines recommend rhythm control for improving symptoms and quality of life in symptomatic patients with atrial fibrillation (AF). However, the long-term prognostic outcomes of rhythm control compared with rate control are still inconclusive. In this meta-analysis, we aimed to assess the effects of early rhythm control compared with rate control on clinical outcomes in newly diagnosed AF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched the PubMed and Embase databases up to August 2022 for randomized and observational studies reporting the associations of early rhythm control (defined as within 12 months of AF diagnosis) with effectiveness outcomes. The primary outcome was a composite of death, stroke, admission to hospital for heart failure (HF), or acute coronary syndrome (ACS). Hazard ratios (HRs) and 95% confidence intervals (CIs) from each study were pooled using a random-effects model, complemented with an inverse variance heterogeneity or quality effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 8 studies involving 447,202 AF patients were included, and 23.5% of participants underwent an early rhythm-control therapy. In the pooled analysis using the random-effects model, compared with rate control, the early rhythm-control strategy was significantly associated with reductions in the primary composite outcome (HR\u2009=\u20090.88, 95% CI: 0.86\u20130.89) and secondary outcomes, including stroke or systemic embolism (HR\u2009=\u20090.78, 95% CI: 0.71\u20130.85), ischemic stroke (HR\u2009=\u20090.81, 95% CI: 0.69\u20130.94), cardiovascular death (HR\u2009=\u20090.83, 95% CI: 0.70\u20130.99), HF hospitalization (HR\u2009=\u20090.90, 95% CI: 0.88\u20130.92), and ACS (HR\u2009=\u20090.86, 95% CI: 0.76\u20130.98). Reanalyses using the inverse variance heterogeneity or quality effects model yielded similar results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our current meta-analysis suggested that early initiation of rhythm control treatment was associated with improved adverse effectiveness outcomes in patients who had been diagnosed with AF within 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>The study protocol was registered to PROSPERO (CRD42021295405).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-022-02545-4","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T20:02:38Z","timestamp":1665604958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Effectiveness of early rhythm control in improving clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Wengen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"issue":"8","key":"2545_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation."},{"issue":"4","key":"2545_CR2","first-page":"e29","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29\u2013322.","journal-title":"Circulation."},{"issue":"11","key":"2545_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627\u20138.","journal-title":"Nat Rev Cardiol."},{"issue":"6","key":"2545_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1161\/HCQ.0000000000000011","volume":"7","author":"AC Ha","year":"2014","unstructured":"Ha AC, Breithardt G, Camm AJ, Crijns HJ, Fitzmaurice GM, Kowey PR, et al. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF). Circ Cardiovasc Qual Outcomes. 2014;7(6):896\u2013904.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"4","key":"2545_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.acvd.2011.11.005","volume":"105","author":"D Caldeira","year":"2012","unstructured":"Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis. 2012;105(4):226\u201338.","journal-title":"Arch Cardiovasc Dis."},{"issue":"10","key":"2545_CR6","doi-asserted-by":"publisher","first-page":"e0186856","DOI":"10.1371\/journal.pone.0186856","volume":"12","author":"NJ Sethi","year":"2017","unstructured":"Sethi NJ, Feinberg J, Nielsen EE, Safi S, Gluud C, Jakobsen JC. The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis. PloS one. 2017;12(10):e0186856.","journal-title":"PloS one."},{"issue":"5","key":"2545_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498.","journal-title":"Eur Heart J."},{"issue":"14","key":"2545_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305\u201316.","journal-title":"N Engl J Med."},{"key":"2545_CR9","doi-asserted-by":"publisher","first-page":"e066450","DOI":"10.1136\/bmj-2021-066450","volume":"375","author":"MK Pope","year":"2021","unstructured":"Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, et al. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. BMJ. 2021;375:e066450.","journal-title":"BMJ."},{"key":"2545_CR10","doi-asserted-by":"publisher","first-page":"n991","DOI":"10.1136\/bmj.n991","volume":"373","author":"D Kim","year":"2021","unstructured":"Kim D, Yang PS, You SC, Sung JH, Jang E, Yu HT, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021;373:n991.","journal-title":"BMJ."},{"issue":"12","key":"2545_CR11","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/clc.23463","volume":"43","author":"C Blomstrom-Lundqvist","year":"2020","unstructured":"Blomstrom-Lundqvist C, Marrouche N, Connolly S, Corp Dit Genti V, Wieloch M, Koren A, et al. Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study. Clin Cardiol. 2020;43(12):1469\u201377.","journal-title":"Clin Cardiol."},{"issue":"5","key":"2545_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.hrthm.2020.12.025","volume":"18","author":"E Yang","year":"2021","unstructured":"Yang E, Tang O, Metkus T, Berger RD, Spragg DD, Calkins HG, et al. The role of timing in treatment of atrial fibrillation: an AFFIRM substudy. Heart rhythm. 2021;18(5):674\u201381.","journal-title":"Heart rhythm."},{"key":"2545_CR13","doi-asserted-by":"publisher","first-page":"e023055","DOI":"10.1161\/JAHA.121.023055","volume":"10","author":"D Kim","year":"2021","unstructured":"Kim D, Yang PS, You SC, Jang E, Yu HT, Kim TH, et al. Comparative effectiveness of early rhythm control versus rate control for cardiovascular outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2021;10:e023055.","journal-title":"J Am Heart Assoc."},{"key":"2545_CR14","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane. 2021; Available from www.training.cochrane.org\/handbook. Accessed 02 May 2022."},{"issue":"1","key":"2545_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev."},{"key":"2545_CR16","volume-title":"The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"GA Wells","year":"2014","unstructured":"Wells GA, Shea BO, Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2014. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 12 May 2022."},{"issue":"4","key":"2545_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14779072.2021.1902307","volume":"19","author":"A Kotalczyk","year":"2021","unstructured":"Kotalczyk A, Ding WY, Gupta D, Wright DJ, Lip GYH. Clinical outcomes following rhythm control for atrial fibrillation: is early better? Expert Rev Cardiovasc Ther. 2021;19(4):277\u201387.","journal-title":"Expert Rev Cardiovasc Ther."},{"issue":"20","key":"2545_CR18","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1161\/CIRCULATIONAHA.121.055163","volume":"144","author":"P Kirchhof","year":"2021","unstructured":"Kirchhof P. In patients with recently diagnosed atrial fibrillation, think anticoagulation and rhythm control. Circulation. 2021;144(20):1587\u20139.","journal-title":"Circulation."},{"issue":"1","key":"2545_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00392-021-01914-y","volume":"111","author":"M Proietti","year":"2022","unstructured":"Proietti M, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, et al. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. Clin Res Cardiol. 2022;111(1):70\u201384.","journal-title":"Clin Res Cardiol."},{"key":"2545_CR20","doi-asserted-by":"publisher","unstructured":"Kany S, Cardoso VR, Bravo L, Williams JA, Schnabel R, Fabritz L, et al. Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank. Heart. 2022. https:\/\/doi.org\/10.1136\/heartjnl-2022-321196 Online ahead of print.","DOI":"10.1136\/heartjnl-2022-321196"},{"issue":"11","key":"2545_CR21","doi-asserted-by":"publisher","first-page":"e024214","DOI":"10.1161\/JAHA.121.024214","volume":"11","author":"J Dickow","year":"2022","unstructured":"Dickow J, Kirchhof P, Van Houten HK, Sangaralingham LR, Dinshaw LHW, Friedman PA, et al. Generalizability of the EAST-AFNET 4 trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation. J Am Heart Assoc. 2022;11(11):e024214.","journal-title":"J Am Heart Assoc."},{"key":"2545_CR22","doi-asserted-by":"publisher","unstructured":"Chao TF, Chan YH, Chiang CE, Tuan TC, Liao JN, Chen TJ, et al. Early rhythm control and the risks of ischemic stroke, heart failure, mortality, and adverse events when performed early (<3 months): a nationwide cohort study of newly diagnosed patients with atrial fibrillation. Thromb Haemost. 2022. https:\/\/doi.org\/10.1055\/a-1807-0336 Online ahead of print.","DOI":"10.1055\/a-1807-0336"},{"issue":"9244","key":"2545_CR23","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(00)03230-X","volume":"356","author":"SH Hohnloser","year":"2000","unstructured":"Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789\u201394.","journal-title":"Lancet."},{"issue":"23","key":"2545_CR24","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa021375","volume":"347","author":"IC Van Gelder","year":"2002","unstructured":"Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834\u201340.","journal-title":"N Engl J Med."},{"issue":"23","key":"2545_CR25","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1056\/NEJMoa021328","volume":"347","author":"DG Wyse","year":"2002","unstructured":"Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825\u201333.","journal-title":"N Engl J Med."},{"issue":"10","key":"2545_CR26","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/S0735-1097(03)00332-2","volume":"41","author":"J Carlsson","year":"2003","unstructured":"Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690\u20136.","journal-title":"J Am Coll Cardiol."},{"issue":"9","key":"2545_CR27","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.hrthm.2013.05.013","volume":"10","author":"TJ Bunch","year":"2013","unstructured":"Bunch TJ, May HT, Bair TL, Johnson DL, Weiss JP, Crandall BG, et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart rhythm. 2013;10(9):1257\u201362.","journal-title":"Heart rhythm."},{"issue":"2","key":"2545_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0008-6363(02)00258-4","volume":"54","author":"M Allessie","year":"2002","unstructured":"Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54(2):230\u201346.","journal-title":"Cardiovasc Res."},{"issue":"12","key":"2545_CR29","first-page":"1764","volume":"21","author":"G Boriani","year":"2019","unstructured":"Boriani G, Blomstr\u00f6m-Lundqvist C, Hohnloser SH, Bergfeldt L, Botto GL, Capucci A, et al. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace. 2019;21(12):1764\u201375.","journal-title":"Europace."},{"issue":"7","key":"2545_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMoa0803778","volume":"360","author":"SH Hohnloser","year":"2009","unstructured":"Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668\u201378.","journal-title":"N Engl J Med."},{"issue":"6","key":"2545_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jamacardio.2021.0852","volume":"6","author":"MK Turagam","year":"2021","unstructured":"Turagam MK, Musikantow D, Whang W, Koruth JS, Miller MA, Langan MN, et al. Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a meta-analysis of randomized clinical trials. JAMA Cardiol. 2021;6(6):697\u2013705.","journal-title":"JAMA Cardiol."},{"issue":"10","key":"2545_CR32","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/archinte.165.10.1185","volume":"165","author":"DG Sherman","year":"2005","unstructured":"Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med. 2005;165(10):1185\u201391.","journal-title":"Arch Intern Med."},{"issue":"20","key":"2545_CR33","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/eurheartj\/ehs348","volume":"34","author":"MG Whitbeck","year":"2013","unstructured":"Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481\u20138.","journal-title":"Eur Heart J."},{"issue":"5","key":"2545_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jacep.2022.02.014","volume":"8","author":"D Kim","year":"2022","unstructured":"Kim D, Yang PS, You SC, Jang E, Yu HT, Kim TH, et al. Age and outcomes of early rhythm control in patients with atrial fibrillation: nationwide cohort study. JACC Clin Electrophysiol. 2022;8(5):619\u201332.","journal-title":"JACC Clin Electrophysiol."},{"issue":"4","key":"2545_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jacc.2022.04.058","volume":"80","author":"A Goette","year":"2022","unstructured":"Goette A, Borof K, Breithardt G, Camm AJ, Crijns H, Kuck KH, et al. Presenting pattern of atrial fibrillation and outcomes of early rhythm control therapy. J Am Coll Cardiol. 2022;80(4):283\u201395.","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"2545_CR36","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/eurheartj\/ehab593","volume":"43","author":"S Willems","year":"2022","unstructured":"Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns H, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022;43(12):1219\u201330.","journal-title":"Eur Heart J."},{"issue":"11","key":"2545_CR37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.121.056323","volume":"144","author":"A Rillig","year":"2021","unstructured":"Rillig A, Magnussen C, Ozga AK, Suling A, Brandes A, Breithardt G, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. circulation. 2021;144(11):845\u201358.","journal-title":"circulation."},{"key":"2545_CR38","doi-asserted-by":"publisher","unstructured":"Ding WY, Calvert P, Gupta D, Huisman MV, Lip GYH. Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II\/III of the GLORIA-AF registry. Clin Res Cardiol. 2022. https:\/\/doi.org\/10.1007\/s00392-022-02022-1 Online ahead of print.","DOI":"10.1007\/s00392-022-02022-1"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02545-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02545-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02545-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T20:02:45Z","timestamp":1665604965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02545-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2545"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02545-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"25 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}